Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The team is called Team ADB, for “AI-Empowered Design of Bispecific Antibodies.”
April 16, 2026
By: Patrick Lavery
Content Marketing Editor
BioMed X has launched its first research team in France, at the XSeed Labs incubator on Servier’s R&D campus. This location, at Paris-Saclay University, is hosted at the Spartners facility operated jointly by Servier and BioLabs.
The research team’s name, Team ADB, stands for “AI-Empowered Design of Bispecific Antibodies.” BioMed X says it helps the company establish a presence in one of the fastest-growing life science ecosystems in Europe.
Tomabu Adjobimey, PhD, leads the research team. He is Associate Professor of Immunology and Microbiology at the University of Abomey-Calavi in Benin.
“Our goal is to develop an AI-driven platform that integrates structural modeling, machine learning, and experimental validation,” Adjobimey said. “By enabling more predictive and structure-aware antibody engineering, this approach could significantly accelerate the discovery of innovative biologic therapeutics.”
Adjobimey will get assistance from Paula Wagner Egea, PhD, BioMed X France Managing Director and Site Head.
“This XSeed Labs team represents an important milestone for BioMed X as we establish our presence in France,” she said. “We are creating a unique environment for interdisciplinary innovation at the intersection of artificial intelligence and biomedical research. With Team ADB and our partners at Servier, we are bringing fresh thinking to one of the most exciting frontiers.”
To that end, BioMed X and Servier claim bispecific antibodies represent one of the most promising classes of biologic therapeutics. As they can engage two molecular targets simultaneously, they hold potential for new treatment strategies in oncology and immunology.
It will now be the research team’s task to tackle bispecific antibodies’ engineering challenges. These include structural constraints and the limited predictability of dual-target interactions.
Ultimately, however, the goals for these therapeutics are reliable stability, specificity, and manufacturability.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !